AOD-9604: What a Fragment Means

Proxiva Compliance DeskResearch-use standards and labelling

The single most consequential fact about AOD-9604 is grammatical rather than chemical: it is a fragment, and almost everything written about it in secondary sources describes it as though it were a version of the parent molecule. It is not. This page sets out what that distinction costs a researcher who ignores it, what the material actually is, and what verification a fragment specifically requires.

What does “a fragment” actually mean here?

It means a defined section of a larger molecule, synthesised on its own. AOD-9604 corresponds to the terminal region of the growth hormone sequence — a short piece of a much larger protein.

The reasoning error that follows is common and expensive: assuming the fragment carries the parent's described activities. It does not, and there is no general principle by which it would. Cutting a molecule changes its size, its three-dimensional structure and which receptors it can engage. Anything a researcher wants to claim about the fragment must have been demonstrated for the fragment. Literature on the intact hormone is literature on a different molecule.

This is the same discipline that applies to BPC-157 — also a fragment, derived from a protein identified in gastric juice — and to TB-500, a synthetic fragment associated with the actin-binding region of a larger protein. All three are fragments, and all three are routinely described using their parents' literature.

How does it relate to the growth-hormone compounds in this catalogue?

It does not, mechanistically. The pituitary compounds here work by causing release of hormone the body has already made. Tesa-morelin is a stabilised analogue of growth hormone releasing hormone acting at the releasing-hormone receptor. Ipamorelin is a five-residue secretagogue acting at the ghrelin receptor. CJC-1295 No DAC is another releasing-hormone analogue.

AOD-9604 is none of those things. It is a piece of the hormone itself rather than something that prompts the hormone's release, so it does not belong in a comparison with them on mechanism — only on the shelf.

What does a fragment require on the certificate?

Mass confirmation, more than anything. A fragment's identity is precisely the thing that can go wrong: a synthesis that produces a sequence one residue short, or that stops early, yields something that is still a peptide and still passes a generic purity assay while being the wrong molecule. Purity answers “how much of this vial is one substance”; mass answers “is that substance the one on the label”.

For AOD-9604 specifically, the second field worth checking is fill quantity. At 5mg per vial and $16.20 per mg, a light fill is a material cost, and fill accuracy is a field certificates frequently omit in favour of the more impressive-looking purity percentage.

How does the cost sit against the rest of the catalogue?

Mid-range. At $16.20 per mg it is well above Glutathione – 1500mg at $0.047/mg and GHK-Cu (Copper Peptide) at $0.70/mg on the 100mg vial, and well below TB-500 at $13.00–$15.00/mg.

As everywhere in this catalogue, the price tracks synthesis difficulty and scale rather than anything about the compound's interest. A short, well-characterised sequence made routinely is cheap; a long or awkward one is not.

Handling

Standard for lyophilised material and unremarkable. Ships dry and tolerates ambient transit; store cold and dark long-term. Bring to room temperature before piercing the stopper so that solvent entering a cold vial does not invite condensation. Reconstitute with Bacteriostatic Water where more than one withdrawal is planned, adding the diluent down the vial wall rather than onto the cake, and swirl rather than shake. In solution the material is markedly less stable than as dry powder, so match the volume to the pace of the work.

What separates suppliers on a page like this

Composition and price are easy to publish and easy to copy. Documentation is neither. The axis on which suppliers in this market genuinely differ is what their certificate reports and whether it is published per batch rather than as a specimen. A specimen certificate demonstrates that a laboratory once tested something; a per-batch certificate tells you about the vial in your hand.

The fields worth checking, in rough order of how often they are missing: quantity per component for any blend, the analytical method named rather than implied, the testing laboratory identified, an endotoxin determination, and a date that corresponds to the batch rather than to the listing. Every batch sold here publishes its certificate on the test results page.

Two further notes on handling that apply to every compound referenced above. Lyophilised material ships dry and tolerates ambient transit; long-term storage is cold and dark. Bring a vial to room temperature before piercing the stopper, because solvent entering a cold vial invites condensation. Reconstitute with Bacteriostatic Water where more than one withdrawal is planned — the preservative is the entire reason to prefer it over sterile water — adding solvent down the wall rather than onto the cake, and swirling rather than shaking.

Why a blend name is not a specification

Almost every named preparation in this market — Wolverine, Glow, Klow and the rest — originated in forum usage rather than in any standards body. Nobody registered the name, nobody defined it, and no authority polices it. The practical consequence is that two suppliers can both list a product under the same name and ship vials that differ by a factor of two or more in total mass and in the ratio between components.

This is why composition published elsewhere for these names frequently describes well under half the totals quoted here, and it is why comparing two vendors on price alone produces a meaningless answer. A cheaper vial carrying the same name may simply contain less. The only comparison that means anything is milligrams of each named component against price, taken from each supplier's own published composition — and where a supplier does not publish per-component quantities, there is no comparison to make.

The same logic applies to any review or ranking of these products that does not state composition. A page comparing five vendors' versions of a named blend without listing what is in each one is comparing labels, not materials.

Reading a certificate without taking it on trust

Most certificates in this market are genuine and most are also thinner than they appear. Four habits separate a document that means something from one that merely exists. First, check that the batch or lot number on the certificate matches the number on the vial — a certificate that names no batch is a specimen, and a specimen tells you a laboratory once tested something. Second, check the date: a certificate predating the batch it purports to describe is a filing error at best. Third, read what was actually measured. “Purity >99%” by an unnamed method is a claim; “99.2% by RP-HPLC at 214nm” is a measurement. Fourth, look for what is absent — mass confirmation, endotoxin, and for any metal-containing complex the metal determination itself.

None of this requires analytical training. It requires reading the document as a record rather than as a reassurance, and noticing which fields are populated. A supplier publishing per-batch certificates with named methods is making a checkable commitment; one publishing a single undated specimen is not.

What this page does not claim

Nothing here describes an intended use in humans, and no outcome of any kind is asserted. The material is supplied for in-vitro laboratory and research use only. Where a mechanism is described it is described as reported in the literature for that compound, and the searches below return that literature directly — including whatever currently contradicts the framing above. Proxiva does not curate those results.

Where to read the primary literature

Proxiva does not summarise findings on behalf of a researcher. These are live searches against the two public registries, not curated citations — they return whatever is currently indexed, including results that contradict the framing above.

• PubMed: AOD-9604 · ClinicalTrials.gov
• PubMed: growth hormone fragment 176-191 · ClinicalTrials.gov
• PubMed: hGH fragment · ClinicalTrials.gov
• PubMed: lipolytic peptide fragment · ClinicalTrials.gov

Frequently asked questions

All materials listed are supplied strictly for in-vitro laboratory and research use. They are not drugs, foods or cosmetics, are not for human or veterinary use, and nothing on this page describes an intended use in humans. Figures quoted are catalogue list prices at the time of writing and change without notice.